Ginseng saponins show complementary stroke protection through distinct molecular pathways

Ischemic stroke kills and disables more people than any other type of stroke—it accounts for roughly 85 percent of all cases—and the treatments we have now are narrow. They can restore blood flow if you catch the stroke early enough and the patient qualifies, but options for protecting the brain tissue that's starved of oxygen, or for helping it recover afterward, remain thin. Two plants used for centuries in Chinese medicine, Panax notoginseng and Panax ginseng, have long been credited with activating blood and replenishing vital energy. Modern laboratory work has found that compounds called saponins extracted from both plants carry anti-inflammatory, antioxidant, and cell-protective properties. But until recently, scientists couldn't see exactly where in the brain these compounds were doing their work, or how their effects differed from one plant to the other.

A team led by Jie Liao at Zhejiang University set out to map those differences with precision. They induced permanent stroke in male mice by blocking the middle cerebral artery, then treated some animals with saponins from P. notoginseng, others with saponins from P. ginseng, and a control group with edaravone, a drug already used clinically for stroke. The results were striking. At a dose of 200 milligrams per kilogram of body weight, both ginseng preparations cut the severity of neurological deficits roughly in half compared to untreated stroke mice. P. notoginseng reduced the volume of dead brain tissue from 30.73 percent to 11.70 percent—matching the performance of edaravone—while P. ginseng brought it down to 13.33 percent. Seven-day survival jumped from 25 percent in untreated animals to 75 percent with P. notoginseng and 50 percent with P. ginseng. Tissue samples showed both treatments reduced swelling, neuronal death, and the loss of Nissl bodies, the cellular structures that reflect healthy nerve function.

But the real insight came from spatial transcriptomics, a technique that maps gene activity while preserving the physical location of cells within tissue. The researchers collected samples from 384 distinct spots across brain sections from sham-operated mice, untreated stroke mice, and mice treated with each ginseng preparation. They focused on eight spots that showed the largest disease-related changes in gene expression—areas corresponding to the ischemic penumbra, the ring of threatened tissue surrounding the dead core of the stroke. When they analyzed which genes were turned on or off in each treatment group, a pattern emerged. Both saponin preparations regulated shared pathways involved in moving materials within mitochondria, organizing proteins, and maintaining the tight junctions that form the blood-brain barrier. But P. notoginseng saponins preferentially activated genes related to the cytoskeleton—the structural scaffolding inside cells—and to actin filaments, the protein fibers that give cells their shape. P. ginseng saponins, by contrast, more strongly influenced genes involved in the tricarboxylic acid cycle and the assembly of mitochondrial complexes, the machinery that generates cellular energy.

Western blotting, a technique that measures specific proteins, confirmed these molecular signatures. P. notoginseng more powerfully restored two proteins called Rac1 and VE-cadherin, which are central to rebuilding the cytoskeleton and repairing the endothelial cells that line blood vessels. P. ginseng exerted stronger effects on SDHA and ATP5A, mitochondrial proteins essential for energy production. Both treatments increased levels of Nrf2, a master regulator of antioxidant defenses, suggesting they share a common mechanism for neutralizing damaging free radicals.

The findings offer a spatially resolved explanation for why these two plants, though both protective, appear to work through different routes. P. notoginseng seems to prioritize early vascular repair and structural remodeling—shoring up the blood-brain barrier and the cellular architecture that has been damaged by stroke. P. ginseng appears to lean more heavily toward metabolic support, restoring the energy-production capacity of mitochondria to help neurons survive and eventually recover. This distinction could matter clinically: if one compound is better at stopping immediate damage while the other excels at supporting longer-term healing, they might be deployed at different stages of stroke recovery.

The caveats are substantial. The experiments were conducted in mice over a 24-hour window, a narrow slice of the stroke timeline. Whether these protective effects hold in humans, whether they persist beyond the first day, and whether the stage-specific benefits the researchers hypothesize actually translate to better outcomes in patients—all of that remains unknown. The researchers themselves note that future work will need to include additional time points, detailed chemical analysis of the saponin preparations, more sophisticated spatial imaging techniques, and experiments designed to prove cause and effect rather than mere correlation. Until those studies are done, the findings remain a compelling proof of concept: two traditional remedies, working through distinct but complementary molecular pathways, both capable of reducing stroke damage in living tissue.